|
1
|
Megwalu UC and Moon PK: Thyroid cancer
incidence and mortality trends in the United States: 2000–2018.
Thyroid. 32:560–570. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tuttle RM, Ahuja S, Avram AM, Bernet VJ,
Bourguet P, Daniels GH, Dillehay G, Draganescu C, Flux G, Führer D,
et al: controversies, consensus, and collaboration in the use of
131I therapy in differentiated thyroid cancer: A joint
statement from the American thyroid association, the European
association of nuclear medicine, the society of nuclear medicine
and molecular imaging, and the European thyroid association.
Thyroid. 29:461–470. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xing M: Molecular pathogenesis and
mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xing M, Alzahrani AS, Carson KA, Viola D,
Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, et al:
Association between BRAF V600E mutation and mortality in patients
with papillary thyroid cancer. JAMA. 309:1493–1501. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moon S, Song YS, Kim YA, Lim JA, Cho SW,
Moon JH, Hahn S, Park DJ and Park YJ: Effects of coexistent
BRAFV600E and TERT promoter mutations on poor clinical
outcomes in papillary thyroid cancer: A meta-analysis. Thyroid.
27:651–660. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bournaud C, Descotes F, Decaussin-Petrucci
M, Berthiller J, de la Fouchardière C, Giraudet AL,
Bertholon-Gregoire M, Robinson P, Lifante JC, Lopez J and
Borson-Chazot F: TERT promoter mutations identify a high-risk group
in metastasis-free advanced thyroid carcinoma. Eur J Cancer.
108:41–49. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Valero C, Eagan A, Adilbay D, Matsuura D,
Harries V, Shaha AR, Shah JP, Tuttle RM, Akhmedin D, Pinheiro RA,
et al: A clinical nomogram to predict survival outcomes in patients
with well-differentiated thyroid cancer. Thyroid. 35:397–405. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei M, Wang R, Zhang W, Zhang J, Fang Q,
Fang Z, Liu B and Li Y: Landscape of gene mutation in Chinese
thyroid cancer patients: Construction and validation of lymph node
metastasis prediction model based on clinical features and gene
mutation marker. Cancer Med. 12:12929–12942. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wen R, Zhao M, Chen C, Yang Y and Zhang B:
A novel nomogram integrated with preablation stimulated
thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio
to predict the therapeutic response of intermediate- and high-risk
differentiated thyroid cancer patients: A bi-center retrospective
study. Endocrine. 84:989–998. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li S, Yun M, Hong G, Tian L, Yang A and
Liu L: Development and validation of a nomogram for preoperative
prediction of level VII nodal spread in papillary thyroid cancer:
Radiologic-pathologic correlation. Surg Oncol. 37:1015202021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Y, Wang J, Hui J, Hou G, He W, Sun T,
Gao L, Wei Y, Zhang W, Zheng L, et al: Postoperative nomogram for
predicting involved lymph node in differentiated thyroid carcinoma:
An observational study. Future Oncol. 21:2785–2793. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Persoon ACM, Links TP, Wilde J, Sluiter
WJ, Wolffenbuttel BHR and van den Ouweland JMW: Thyroglobulin (Tg)
recovery testing with quantitative Tg antibody measurement for
determining interference in serum Tg assays in differentiated
thyroid carcinoma. Clin Chem. 52:1196–1199. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Neshandar Asli I, Siahkali AS, Shafie B,
Javadi H and Assadi M: Prognostic value of basal serum
thyroglobulin levels, but not basal antithyroglobulin antibody
(TgAb) levels, in patients with differentiated thyroid cancer. Mol
Imaging Radionucl Ther. 23:54–59. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American thyroid association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American thyroid association
guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duda OR, Slipetsky RR and Bojko NI:
Principles of medullary thyroid cancer staging according to AJCC
TNM 8th edition. AML. 27:101–116. 2021. View Article : Google Scholar
|
|
16
|
Suh S, Kim YH, Goh TS, Lee J, Jeong DC, Oh
SO, Hong JC, Kim SJ, Kim IJ and Pak K: Outcome prediction with the
revised American joint committee on cancer staging system and
American thyroid association guidelines for thyroid cancer.
Endocrine. 58:495–502. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ghaznavi SA, Ganly I, Shaha AR, English C,
Wills J and Tuttle RM: Using the American thyroid association
risk-stratification system to refine and individualize the American
joint committee on cancer eighth edition disease-specific survival
estimates in differentiated thyroid cancer. Thyroid. 28:1293–1300.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Balachandran VP, Gonen M, Smith JJ and
DeMatteo RP: Nomograms in oncology: More than meets the eye. Lancet
Oncol. 16:e173–e180. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun J, Jiang Q and Wang X, Liu W and Wang
X: Nomogram for preoperative estimation of cervical lymph node
metastasis risk in papillary thyroid microcarcinoma. Front
Endocrinol (Lausanne). 12:6139742021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang R, Tang Z, Wu Z, Xiao Y, Li J, Zhu J,
Zhang X and Ming J: Construction and validation of nomograms to
reduce completion thyroidectomy by predicting lymph node metastasis
in low-risk papillary thyroid carcinoma. Eur J Surg Oncol.
49:1395–1404. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Q, Yu B, Zhang S, Wang D, Xiao Z,
Meng H, Dong L, Zhang Y, Wu J, Hou Z, et al: Papillary thyroid
carcinoma: correlation between molecular and clinical features. Mol
Diagn Ther. 28:601–609. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fagin JA and Wells SA Jr: Biologic and
clinical perspectives on thyroid cancer. N Engl J Med.
375:1054–1067. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nappi C, Megna R, Zampella E, Volpe F,
Piscopo L, Falzarano M, Vallone C, Pace L, Petretta M, Cuocolo A
and Klain M: External validation of a predictive model for
post-treatment persistent disease by 131I whole-body
scintigraphy in patients with differentiated thyroid cancer. Eur J
Nucl Med Mol Imaging. 52:2867–2874. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang X, Zheng X, Zhu J, Li Z and Wei T: A
nomogram and risk classification system for predicting
cancer-specific survival in tall cell variant of papillary thyroid
cancer: A SEER-based study. J Endocrinol Invest. 46:893–901. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim DH, Jung JH, Son SH, Kim CY, Hong CM,
Jeong SY, Lee SW, Lee J and Ahn BC: Difference of clinical and
radiological characteristics according to radioiodine avidity in
pulmonary metastases of differentiated thyroid cancer. Nucl Med Mol
Imaging. 48:55–62. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lamartina L, Durante C, Lucisano G, Grani
G, Bellantone R, Lombardi CP, Pontecorvi A, Arvat E, Felicetti F,
Zatelli MC, et al: Are evidence-based guidelines reflected in
clinical practice? An analysis of prospectively collected data of
the Italian thyroid cancer observatory. Thyroid. 27:1490–1497.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Anderson H, Lim KH, Gull S, Oprean R,
Spence K and Cvasciuc T: Predicting clinical outcomes of patients
with serum thyroglobulin antibodies after thyroidectomy for
differentiated thyroid cancer: A retrospective study from a UK
regional center. Minerva Endocrinol (Torino). 49:60–68.
2024.PubMed/NCBI
|
|
28
|
Zhang Y, Hua W, Zhang X, Peng J, Liang J
and Gao Z: The predictive value for excellent response to initial
therapy in differentiated thyroid cancer: Preablation-stimulated
thyroglobulin better than the TNM stage. Nucl Med Commun.
39:405–410. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu L, Li Q, Ge Z, Lu Y, Lin C, Lv J, Huang
J, Mu X and Fu W: Development of a predictive nomogram for
intermediate-risk differentiated thyroid cancer patients after
fixed 3.7GBq (100mCi) radioiodine remnant ablation. Front
Endocrinol (Lausanne). 15:13616832024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Garo ML, Deandreis D, Campennì A,
Vrachimis A, Petranovic Ovcaricek P and Giovanella L: Accuracy of
papillary thyroid cancer prognostic nomograms: A systematic review.
Endocr Connect. 12:e2204572023.
|
